IMPACT OF COLCHICINE ON THE CLINICAL OUTCOME OF COVID-19

Emad R. Issak
{"title":"IMPACT OF COLCHICINE ON THE CLINICAL OUTCOME OF COVID-19","authors":"Emad R. Issak","doi":"10.21608/asmj.2022.270144","DOIUrl":null,"url":null,"abstract":": Background: Because of the emergence of the pandemic of SARS-Cov2 infection and the Global burden of COVID-19 on the worldwide healthcare systems, it became mandatory for all researchers to search for better preventive as well treatment strategies. Aim of the Work : The aim of the work is to study the effects of colchicine on the COVID-19 patients' clinical outcomes and the inflammatory markers during the disease. Material and Methods: This comparative, randomized controlled study has been conducted on patients confirmed to have COVID-19 attending Ain Shams Isolation hospital from Feb-2021 and May-2021. The A were randomized with 130 assigned to each group follows: The Study Group (colchicine group) (n=130): included patients who received COVID-19 treatment protocol plus colchicine according to the study protocol. The Control Group (n=130): included patients who received COVID-19 treatment protocol only without colchicine. Results : Both groups were comparable regarding age, BMI, and gender. Females constituted 58.1% & 56.0% of cases in the colchicine group & the control group, respectively. At presentation, as regards the severity, both groups are comparable (p = 0.553). In day 14, the improvement in the clinical status in the colchicine group 0.64 (0.96) is significantly (p-value = 0.002) higher than in the control group 0.28 (0.99). Conclusion : The beneficial effect of colchicine in COVID-19 cases is self-evident for both the clinical status and laboratory evaluation","PeriodicalId":7450,"journal":{"name":"Ain Shams Medical Journal","volume":"161 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ain Shams Medical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21608/asmj.2022.270144","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

: Background: Because of the emergence of the pandemic of SARS-Cov2 infection and the Global burden of COVID-19 on the worldwide healthcare systems, it became mandatory for all researchers to search for better preventive as well treatment strategies. Aim of the Work : The aim of the work is to study the effects of colchicine on the COVID-19 patients' clinical outcomes and the inflammatory markers during the disease. Material and Methods: This comparative, randomized controlled study has been conducted on patients confirmed to have COVID-19 attending Ain Shams Isolation hospital from Feb-2021 and May-2021. The A were randomized with 130 assigned to each group follows: The Study Group (colchicine group) (n=130): included patients who received COVID-19 treatment protocol plus colchicine according to the study protocol. The Control Group (n=130): included patients who received COVID-19 treatment protocol only without colchicine. Results : Both groups were comparable regarding age, BMI, and gender. Females constituted 58.1% & 56.0% of cases in the colchicine group & the control group, respectively. At presentation, as regards the severity, both groups are comparable (p = 0.553). In day 14, the improvement in the clinical status in the colchicine group 0.64 (0.96) is significantly (p-value = 0.002) higher than in the control group 0.28 (0.99). Conclusion : The beneficial effect of colchicine in COVID-19 cases is self-evident for both the clinical status and laboratory evaluation
秋水仙碱对COVID-19临床转归的影响
背景:由于SARS-Cov2感染大流行的出现以及COVID-19给全球医疗系统带来的全球负担,所有研究人员都必须寻找更好的预防和治疗策略。工作目的:研究秋水仙碱对新冠肺炎患者临床转归及病程炎症指标的影响。材料和方法:本研究对2021年2月至2021年5月至2021年5月在艾因沙姆斯隔离医院确诊的COVID-19患者进行了比较、随机对照研究。实验组(秋水仙碱组)(n=130):纳入根据研究方案接受COVID-19治疗方案加秋水仙碱的患者。对照组(n=130):包括仅接受不含秋水仙碱的COVID-19治疗方案的患者。结果:两组在年龄、BMI和性别方面具有可比性。秋水仙碱组和对照组女性分别占58.1%和56.0%。在就诊时,就严重程度而言,两组具有可比性(p = 0.553)。第14天,秋水仙碱组临床状况改善率0.64(0.96)显著高于对照组0.28 (0.99)(p值= 0.002)。结论:秋水仙碱对COVID-19患者的有益作用,无论是临床状况还是实验室评价都是不言而喻的
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信